Vancouver, Canada, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the international Patent Cooperation Treaty ("PCT") as part of the company's ongoing collaboration with the with Yissum Research Development Company of the Hebrew Universi ...

Vancouver, Canada, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that a new article published by Baraghithy et al, revealed promising results from a recent study on 5- methoxy-2-aminoindane (MEAI) for combating obesity. The study was meticulously conducted by a team ...

Vancouver, Canada, July 31, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today concluded its successful participation at the Psychedelic Medicine – Israel 2024 conference. The event took place in Tel Aviv, Israel, bringing together leading experts and researchers from around the world in th ...

The engagement aims for JS First to conduct comprehensive research on manufacturing and licensing rights for Clearmind's MEAI-based beverages in foreign markets, identify and secure high-quality manufacturing partners in multiple countries and establish relationships with distributors across the globe, including in the U.S., Europe, Africa and Southeast Asia, for widespread market penetration. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development o ...

Vancouver, Canada, July 19, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has announced a strategic engagement with JS First Sdn. Bhd ("JS First"). This partnership aims to source global manufacturers and distributors for Clearmind's groundbreaking MEAI-based alcohol substitute beverages, m ...

The Phase I/IIa clinical trial is a multinational, multi-center, single and multiple dose, tolerability, safety and pharmacokinetic trial of CMND-100 in healthy volunteers and AUD subjects. For further information visit: https://www.clearmindmedicine.com or contact: General Inquiries "The FDA's IND approval for CMND-100 marks a significant step forward in addressing the critical unmet medical needs in AUD, a disease currently lacking effective treatments. Excessive alcohol use is a leading preventable cause ...

"The FDA's IND approval for CMND-100 marks a significant step forward in addressing the critical unmet medical needs in AUD, a disease currently lacking effective treatments. Excessive alcohol use is a leading preventable cause of death in the United States, affecting millions of patients and their families. We believe in the potential of our treatment to improve millions of lives in a safe, easy, and efficient way," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. "Approval to start our first-in-human ...

Core Viewpoint - Clearmind Medicine Inc. has submitted an additional patent application to the USPTO as part of its collaboration with SciSparc Ltd. to develop novel psychedelic-derived therapeutics aimed at addressing under-treated health issues, including obesity and addiction [1][3][4]. Company Overview - Clearmind is a clinical-stage biotech company focused on discovering and developing psychedelic-derived therapeutics to tackle significant health problems, particularly alcohol use disorder [4]. - The company currently holds an intellectual property portfolio consisting of eighteen patent families, including 28 granted patents, and aims to expand its patent holdings opportunistically [10]. Collaboration and Patent Applications - In collaboration with SciSparc, Clearmind has filed a total of twelve patent applications with the USPTO for various proprietary compositions, including the combination of SciSparc's PEA and Clearmind's MEAI compound for treating alcohol use disorder, cocaine addiction, and obesity [3][8]. - The latest patent application specifically refers to the proprietary composition of Clearmind's MEAI compound with Palmitoylethanolamide (PEA) for addressing metabolic syndrome and obesity [8]. Market Context - The global obesity treatment market was valued at $15 billion in 2022 and is projected to grow at a rapid revenue CAGR of 10.0% from 2023 to 2032, driven by the rising prevalence of obesity and advancements in weight loss technologies [9].

TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that an additional patent application with the United States Patent and Trademark Office ("USPTO") was submitted as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind"), a clinical-st ...

Company Overview - Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address significant health issues, including alcohol use disorder [4][5] - The company has filed multiple patent applications in collaboration with SciSparc Ltd. for various proprietary compositions aimed at treating alcohol use disorder, cocaine addiction, obesity, and related metabolic disorders [3][5] Market Insights - The global obesity treatment market was valued at $15 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 10.0% from 2023 to 2032, driven by the rising prevalence of obesity and advancements in weight loss technologies [2] Intellectual Property - Clearmind's intellectual property portfolio includes eighteen patent families with 28 granted patents, and the company plans to pursue additional patents as opportunities arise [7] - A recent patent application pertains to a novel composition combining Clearmind's MEAI compound with Palmitoylethanolamide (PEA) for treating metabolic syndrome and obesity [6]